Understanding how redox balance affects regulatory T cells in organ transplants
Redox homeostasis to capture regulatory T cell heterogeneity in transplant
This study is looking at how certain immune cells called regulatory T cells work in organ transplant patients, with the goal of finding better ways to help these cells do their job so that patients can have a smoother recovery and lower chances of organ rejection.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11012317 on NIH RePORTER |
What this research studies
This research investigates the role of redox homeostasis in regulatory T cells (Tregs) that are crucial for controlling immune responses in organ transplant recipients. The study aims to develop new techniques to assess the functional differences among Tregs, which can vary even among cells that appear similar. By focusing on the metabolic pathways and antioxidant mechanisms that influence Treg function, the research seeks to improve our understanding of how these cells can be better utilized in transplant settings. Patients may benefit from advancements in transplant tolerance and reduced rejection rates through enhanced Treg functionality.
Who could benefit from this research
Good fit: Ideal candidates for this research are organ transplant recipients who may benefit from improved immune regulation.
Not a fit: Patients who are not organ transplant recipients or those with conditions unrelated to T cell regulation may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved transplant outcomes by enhancing the effectiveness of regulatory T cells in preventing organ rejection.
How similar studies have performed: Previous research has shown promise in understanding T cell metabolism and its impact on immune responses, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Fribourg, Miguel — Icahn School of Medicine at Mount Sinai
- Study coordinator: Fribourg, Miguel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.